Total submissions: 7
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000724572 | SCV000233141 | uncertain significance | not provided | 2018-07-27 | criteria provided, single submitter | clinical testing | |
Invitae | RCV000468202 | SCV000545120 | benign | Intellectual disability, autosomal dominant 1 | 2022-10-25 | criteria provided, single submitter | clinical testing | |
Gene |
RCV000724572 | SCV000617113 | benign | not provided | 2019-12-04 | criteria provided, single submitter | clinical testing | |
Athena Diagnostics Inc | RCV000724572 | SCV001476679 | likely benign | not provided | 2020-04-03 | criteria provided, single submitter | clinical testing | |
Ce |
RCV000724572 | SCV002063897 | likely benign | not provided | 2021-11-01 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002354466 | SCV002657145 | uncertain significance | Inborn genetic diseases | 2017-09-28 | criteria provided, single submitter | clinical testing | The p.R200Q variant (also known as c.599G>A), located in coding exon 4 of the MBD5 gene, results from a G to A substitution at nucleotide position 599. The arginine at codon 200 is replaced by glutamine, an amino acid with highly similar properties. This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
Clinical Molecular Genetics Laboratory, |
RCV000678818 | SCV000805004 | uncertain significance | developmental delay with intractable seizures | 2016-11-14 | no assertion criteria provided | clinical testing |